American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction

Kala Visvanathan, Rowan T. Chlebowski, Patricia Hurley, Nananda F. Col, Mary Ropka, Deborah Collyar, Monica Morrow, Carolyn Runowicz, Kathleen I. Pritchard, Karen Hagerty, Banu Arun, Judy Garber, Victor G. Vogel, James L. Wade, Powel Brown, Jack Cuzick, Barnett S. Kramer, Scott M. Lippman

Research output: Contribution to journalReview article

Original languageEnglish (US)
Pages (from-to)196-199
Number of pages4
JournalJournal of oncology practice
Volume5
Issue number4
DOIs
StatePublished - Jul 1 2009

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Visvanathan, K., Chlebowski, R. T., Hurley, P., Col, N. F., Ropka, M., Collyar, D., Morrow, M., Runowicz, C., Pritchard, K. I., Hagerty, K., Arun, B., Garber, J., Vogel, V. G., Wade, J. L., Brown, P., Cuzick, J., Kramer, B. S., & Lippman, S. M. (2009). American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of oncology practice, 5(4), 196-199. https://doi.org/10.1200/JOP.0948502